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SUMMARY
We analysed Mycobacterium tuberculosis strains from children, hospitalized from January 2004
to July 2008 in the largest paediatric hospital complex in Cambodia. Specimens were tested for
drug susceptibility and genotypes. From the 260 children, 161 strains were available. The East
African-Indian genotype family was the most common (59·0%), increasing in frequency with
distance from the Phnom Penh area, while the frequency of the Beijing genotype family strains
decreased. The drug resistance pattern showed a similar geographical gradient: lowest in the
northwest (4·6%), intermediate in the central (17·1%), and highest in the southeastern (30·8%)
parts of the country. Three children (1·9%) had multidrug-resistant tuberculosis. The Beijing
genotype and streptomycin resistance were significantly associated (P<0·001). As tuberculosis in
children reflects recent transmission patterns in the community, multidrug resistance levels inform
about the current quality of the tuberculosis programme.
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INTRODUCTION
The distribution of genotypes in Mycobacterium
tuberculosis isolates from children provides valuable
information on strains that have been circulating
most recently in the community. Similarly, the drug
susceptibility pattern of strains from children is a bet-
ter indicator of recent epidemiological developments
than that of strains obtained from adults [1–3].
While obtaining such information has great appeal,
it is exceedingly difficult to collect specimens from
children that allow isolation of M. tuberculosis.
We have reported on the implementation of a diag-
nostic tuberculosis (TB) laboratory service in a large
paediatric referral hospital in Cambodia [4]. Here we
describe the spoligotype distribution and drug suscep-
tibility pattern profiles of strains isolated from paedia-
tric TB patients. The current investigation aims to
provide insight into the epidemiology of TB sup-
plementary to information from resistance surveys
obtained from adult patients during the past decade
in Cambodia [5–7].
* Author for correspondence: Professor K. Schopfer, Scheuer-
mattweg 43, 3043 Uettligen, Switzerland.
(Email: kurt.schopfer@bluewin.ch)
Epidemiol. Infect. (2015), 143, 910–921. © Cambridge University Press 2014
doi:10.1017/S0950268814001769
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268814001769
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 18:08:36, subject to the Cambridge Core terms of use, available at
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
5
5
0
4
9
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
MATERIAL AND METHODS
Setting
Details of the setting have been described previously
[4]. The Jayavarman VII Hospital in Siem Reap is
the largest of five Kantha Bopha paediatric referral
hospitals in Cambodia. These hospitals cared for
about 120000 hospitalized and 800000 ambulatory
paediatric patients in 2011 [8]. The mycobacteriology
service, established in the Siem Reap hospitals, also
served as a referral centre for specimens from the
Kantha Bopha hospitals in Phnom Penh. The study
period from 1 January 2004 to 15 July 2008 was div-
ided into three phases: Phase 1: from 1 January 2004
to 30 June 2005, establishing laboratory infrastruc-
ture, procedures, and logistics. Phase 2: from 1 July
2005 to 31 March 2006, all children hospitalized
with a clinical diagnosis of TB were systematically
evaluated. Phase 3: from 1 April to 15 July 2008, sam-
pling was limited to children with microbiologically
confirmed TB in order to expand a M. tuberculosis
isolate collection. Sampling in Phnom Penh was not
as systematic as in Siem Reap.
Ethical considerations
At admission to the hospital, the child’s guardian is
requested to provide informed and signed (fingerprint)
consent for the necessary diagnostic and treatment
procedures. This record is kept as a permanent docu-
ment in the patient’s file.
METHODS
Basic laboratory examinations upon admission in-
cluded haematology, biochemistry, and urine examina-
tions in accordance with locally established hospital
standards. Laboratory tests were performed after
obtaining written consent from the child’s guardian.
TB-specific laboratory examinations included col-
lection of clinical specimens for microbiological exam-
ination as described previously [4]. Included were
patients who had at least one positive result with
any of the three methods (bright-field microscopy,
rRNA amplification, culture) on at least one speci-
men. Drug susceptibility testing and genotyping
were performed from strains isolated by culture.
Specimens were homogenized, decontaminated,
neutralized, and centrifuged as described previously
[4]. One aliquot was stored at +4–8 °C locally for up
to 6 months after addition of the antimicrobial cock-
tail PANTA™ (BD, USA) to 0·5%Middlebrook 7H10
agar (Difco, USA) and sent in batches to the collabor-
ating Institute of Infectious Diseases in Bern, Switzer-
land for culture, drug susceptibility testing, and
genotyping.
Culture
One slant of Löwenstein–Jensen medium containing
pyruvate and one BacT/ALERT Mycobacteria bottle
with Mycobacteria antibiotic supplement (bio-
Mérieux, Switzerland) were inoculated with 0·2 and
0·5 ml of the sediments, respectively. Slants of the
solid medium were incubated at 35 °C in ambient air
and BacT/ALERT Mycobacteria process bottles in
the BacT/ALERT Microbial Detection System (bio-
Mérieux) at 35 °C according to the manufacturer’s
recommendations, respectively. Incubation was up to
8 weeks. M. tuberculosis complex isolates were iden-
tified to the species level using the GenoType®
MTBC assay (Hain Life Sciences GmbH, Germany).
Genotyping
The spoligotyping method was performed as de-
scribed previously [9]. Biotin-labelled PCR products
were detected by hybridization onto a spoligotyping
membrane (Isogen Life Science, The Netherlands).
Each test run included purified sterile water and
M. tuberculosis control strain H37RV, and M. bovis
BCG strain P3 controls. The results were analysed
based on the standards provided by the SITVIT data-
base (http://www.pasteur-guadeloupe.fr:8081/SITVITD
emo/index.jsp) [10]. This SpolDB4 international online
database of spoligotype patterns has been established
wherein a clustered pattern is designated a shared inter-
national type (SIT) [11]. During the later study phase the
MIRU-VNTRplus database (http://www.miru-vntrplus.
org) was used [12, 13]. 15-MIRU-VNTR typing fol-
lowed the proposed standard approach [14]. DNA
extraction from cultures was performed in Bern. Ali-
quots of a subset were typed independently in Bern and
at the National Mycobacteria Reference Laboratory,
National Institute for Public Health and the Environ-
ment, Bilthoven, The Netherlands.
Drug susceptibility testing
Drug susceptibilities were assessed using the radio-
metric method in a Bactec 460-TB instrument
(PRISE, Becton Dickinson, Germany). The critical
drug concentrations (in mg/l) were: pyrazinamide,
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100; rifampicin, 2·0; isoniazid, 0·1; streptomycin, 2·0;
and ethambutol, 2·5.
Electronic database and analysis
Data were abstracted from the paper documents as
recorded by healthcare staff and captured in an
EpiData relational database (EpiData Association,
v. 3.1, Denmark). Data were analysed by EpiData
Analysis, v. 2.2 (freely available at http://www.
epidata.dk), OpenEpi (http://www.openepi.com/OE2.
3/Menu/OpenEpiMenu.htm) and Stata v. 12.1 (Stata-
Corp, USA) as appropriate. For categorical variables
we determined proportions with 95% confidence inter-
vals (CIs). Where appropriate, we calculated odds
ratios (ORs) with 95% CIs using the Robins–
Breslow–Greenland method [15]. For continuous vari-
ables we used standard measures of central tendency
such as means and percentiles.
We created categories based on frequencies of four
spoligotypes: (1) the East African-Indian (EAI) geno-
type family, (2) the Beijing genotype family, (3) all
others with a defined spoligotype, and (4) a group of
undefined spoligotypes. We analysed factors that
might be associated with each of these categories,
examining other relevant strain characteristics (drug
susceptibility), their frequency in time (study period),
geographical distribution (patient’s province of resi-
dence), and patient’s characteristics (age, sex, disease
site, HIV status).
A modified Poisson regression approach was ap-
plied to conduct univariable and multivariable analy-
ses and to obtain relative prevalence estimates for the
presence of any drug susceptibility [16]. In the multi-
variable regression we included the SIT and province
group as these were the main characteristics of interest
in the analysis of drug susceptibility. A P value <0·05
was considered statistically significant.
RESULTS
During the study period, 260 children aged <17 years
were diagnosed with microbiologically confirmed TB
(Table 1) [4]. Of these, 162 (62·3%) had TB confirmed
by culture. In 161/162 patients, spoligotypes and
drug susceptibility patterns were determined. The 161
children with M. tuberculosis isolates available are the
subject of this report. These 161 children did not statisti-
cally differ by age and sex from the 99 not included.
Genotyping was independently performed by
two laboratories (Bern and Bilthoven) and revealed
identical results. One hundred of the 161 patients
had a single isolate available for spoligotyping,
32 had two and 27 had three identical isolates.
One child (Table 2, patient A) had three isolates,
two were identical and one with a different spoligotype.
Another child (Table 2, patient B) had five isolates; four
were of the same spoligotype. The 161 children thus had
253 isolates and 163 strains. Because the two children
with two different strains (as confirmed by
MIRU-VNTR typing) belonged to the same ‘undefined
(orphan) spoligotype group’, we could assign each of
the 161 children to one single spoligotype group and
use the child as the unit of analysis.
A first condensation provided 12 SIT groupings
(Table 1). The most frequent spoligotype was
EAI_SOM (n=51, 31·7% of all spoligotypes), fol-
lowed by 32 orphan SITs (19·9%). The next most fre-
quent were EAI5, followed by the Beijing strain
family, EAI2_NTB, and U. The EAI family
accounted for the majority with 95 (59·0%, 95% CI
51·3–66·3) among all spoligotypes.
Drug susceptibility was tested for isoniazid, rifam-
picin, ethambutol, streptomycin, and pyrazinamide.
There were no differences in the drug resistance pat-
tern among the samples fromeachpatient.Of the strains
isolated from the 161 patients, 137 (85·1%) were
susceptible to all five drugs (Table 1). M. tuberculosis
from two children showed mono-resistance to
pyrazinamide.
Grouping of patient provenance
The province of residence was known for 137 (85·1%)
of the 161 children. Children who attended the services
of the hospitals in Siem Reap and Phnom Penh origi-
nated from16of the 24 provinces inCambodia covering
three quarters of the country’s population. Three
groups of provenance were created: (1) the ‘Kampong
Thom group’ with 35 children, (2) the ‘Siem Reap
group’ with 87 children from Siem Reap, five of its
neighbouring provinces (except Kampong Thom),
and 11 children attending the hospital in Siem Reap
but without information on province of residence, (3)
‘the Phnom Penh group’ with 39 children from
Phnom Penh, eight of its neighbouring provinces, and
13 children attending the hospital in Phnom Penh but
without information on province of residence (Fig. 1).
Univariable analysis of genotyping results
In the univariable analysis, two characteristics
emerged as being associated with the spoligotype:
the province group and the drug susceptibility result.
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Children from the Siem Reap group contained the
EAI spoligotype significantly more frequently com-
pared to children from the Phnom Penh group
(Table 3). Conversely, children from the Phnom
Penh group had the highest prevalence of the Beijing
family spoligotype, and those from the Siem Reap
group the lowest (trend not statistically significant,
P=0·06).
Children with an EAI spoligotype were significantly
more likely to have a drug-susceptible strain then
children not having an EAI spoligotype. Focusing
on the Beijing strain family, children with any drug
resistance were more likely to have a Beijing
spoligotype.
Univariable analysis of drug susceptibility testing
results
Because pyrazinamide is not usually tested in drug
surveys nor part of international proficiency test
Table 1. Characteristics of Mycobacterium tuberculosis strains among children by study phase, type of
microbiological diagnosis, genotype, and drug susceptibility pattern. Cambodia, Kantha Bopha hospitals,
1 January 2004 to 15 July 2008
Characteristic Phase 1 Phase 2 Phase 3
Total
Number col %
Microbiologically confirmed* 67 97 96 260 100·0
RNA pos., culture pos., Ziehl pos.† 38 40 55 133 51·2
RNA pos., culture pos., Ziehl neg.† 2 4 19 25 9·6
RNA neg., culture pos., Ziehl pos.† 1 3 0 4 1·5
RNA pos., culture neg., Ziehl pos.† 8 11 8 27 10·4
RNA pos., culture neg., Ziehl neg.† 1 32 14 47 18·1
RNA neg., culture neg., Ziehl pos.† 17 7 0 24 9·2
Culture-positive 41 47 74 162 62·3
Culture-positive with spoligotype and DST 41 46 74 161 100·0
Spoligotypes
EAI5_SOM 11 14 26 51 31·7
Undefined 4 7 21 32 19·9
EAI5 11 6 8 25 15·5
Beijing 5 7 8 20 12·4
EAI2_NTB 3 7 7 17 10·6
U 2 4 4 10 6·2
T1 1 0 0 1 0·6
LAM9 1 0 0 1 0·6
H1 1 0 0 1 0·6
EAI4_VNM 1 0 0 1 0·6
EAI2_MANILA 1 0 0 1 0·6
MANU1 0 1 0 1 0·6
Drug susceptibility pattern‡
- - - - - 31 40 66 137 85·1
H- - - - 1 1 2 4 2·5
HRE- - 0 0 1 1 0·6
HR- -Z 2 0 0 2 1·2
H- -S- 2 2 0 4 2·5
-R- - - 0 0 1 1 0·6
- - -S- 4 3 3 10 6·2
- - - -Z 1 0 1 2 1·2
H, Isoniazid; R, rifampicin; E, ethambutol; S, streptomycin; Z, pyrazinamide; DST, drug susceptibility test.
* RNA pos./neg., Positive/negative on rRNA amplification test; culture pos./neg., positive/negative on culture; Ziehl pos./neg.,
positive/negative on microscopy using the Ziehl–Neelsen technique.
† Percentages in last column refer to confirmed cases.
‡ - - - - -, Susceptible to all five drugs. The symbol for the drug interrupting the sequence of five hyphens indicates resistance to
that drug.
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Table 2. Summary of the spoligotyping and 15-MIRU-VNTR typing in two children withMycobacterium tuberculosis isolates obtained from sampling over four
(patient A) and seven (patient B) consecutive days, respectively. In patient A the spoligotype and MIRU-VNTR typing results were identical in the samples
obtained within the first 2 days following hospitalization, the spoligotype was different in the sample obtained at day 4 and there were differences at three genetic
loci in MIRU-VNTR typing in the three samples available for testing. In patient B five samples were available; the spoligotype in sample 2 was different from four
other isolates; there was one insignificant MIRU-VNTR type variation among all five samples available
Patient Age (yr) Sex DST Octal code
MIRU-VNTR type
580 2996 802 960 1644 3192 424 577 2165 2401 3690 4156 2163b 1955 4652
A 12·2 M Susceptible 777777777003731 7 7 3 4 2 4 2 4 6 2 4 1 2 5 4
Susceptible 777777777003731 7 7 3 4 2 4 2 4 6 2 4 1 2 5 4
n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Susceptible 777777737413731 7 2 3 4 2 5 2 4 6 2 4 1 2 5 6
B 14·0 F Susceptible 777607777740771 2 2 5 2 1 3 2 4 2 2 5 2 2 3 5
Susceptible 777607777740740 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Susceptible 777607777740771 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Susceptible 777607777740771 2 7 5 2 1 3 2 4 2 2 5 2 2 3 5
Susceptible 777607777740771 2 2 5 2 1 3 2 4 2 2 5 2 2 3 5
n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
DST, Drug susceptibility test; n.d., not done; F, female, M, male.
In the Octal code, the gene(s) with differences in repeat testing are shown bold and underlined. In the MIRU-VNTR type, gene loci with difference on repeat testing are shown
with a grey background.
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panels and because ethambutol results are not very
reliable [17], we focused our analyses on isoniazid,
rifampicin, and streptomycin. Considering these
drugs, 22 (13·7%, 95% CI 9·2–19·8) strains showed re-
sistance against at least one drug, 14 (8·7%) to strepto-
mycin, 11 (6·8%) to isoniazid, and three (1·9%, 95%
CI 0·6–5·3) revealed multidrug resistance (resistance
to at least isoniazid and rifampicin) (Table 4).
The prevalence of resistance by date of isolation,
provenance, andperson (age, sex,disease site,HIVsero-
status) was also examined. Beijing spoligotype and
the patient’s provenance were significantly associated
with any drug resistance, but none of the other factors.
Multivariable analysis
The results of the relative prevalence of any drug
resistance by various patient characteristics in the uni-
variable approach and the results of the adjusted
multivariable analysis are summarized in Table 5.
The variable ‘HIV infection’ was omitted from the
analysis because the proportion of children with a
missing result was large and precluded a meaningful
analysis. The geographical gradient observed in the
crude analysis was somewhat reduced when adjusted
for spoligotype but remained strong.
To determine the type of drug resistance that was
actually responsible for the gradient we used the
above groups. Among these, we defined two sub-
groups with, respectively, (1) streptomycin resistance
but no isoniazid resistance (10/14 cases with any strep-
tomycin and 22 cases with any resistance) and (2) iso-
niazid resistance but not streptomycin resistance (7/11
with any isoniazid) cases (Table 1). The geographical
gradient is largely attributable to streptomycin, but
not to isoniazid resistance (Fig. 2). Because 10/14
streptomycin-resistant strains were mono-resistant
and four had a combined resistance against isoniazid
Fig. 1. Map of Cambodia with 24 provinces/municipalities. Light grey shading: Siem Reap group; intermediate grey
shading: Kampong Thom; dark grey shading: Phnom Penh group of provinces. The location of the Jayavarman VII
Hospital in Siem Reap province is shown as a solid symbol (●). Cambodia, Kantha Bopha hospitals, 1 January 2004 to
15 July 2008.
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and streptomycin, the influence of streptomycin resist-
ance on any resistance is substantial. Streptomycin re-
sistance was also significantly associated with strain
family: 4/10 streptomycin mono-resistant strains were
of the Beijing genotype, while only 16/151 other strains
were (OR 5·6, 95% CI 1·4–22·1). Adjusted for province
group, the ORwas slightly lower (3·7). Due to the small
sample size, the confidence interval (0·77–18·1) was too
wide to remain meaningful, but nevertheless suggest-
ed that the geographical gradient still held. There was
no association between Beijing strains and isoniazid
(but no streptomycin) resistance (OR 1·2).
DISCUSSION
TB in children reflects recent transmission patterns
in the community, in contrast to adult TB. The
M. tuberculosis genotype distribution among children
mirrors the cumulative history of transmission up to
the present time. Drug susceptibility patterns inform
about both the recent past of drug use (e.g. strepto-
mycin and isoniazid resistance) and current treatment
quality (such as multidrug resistance).
The most conspicuous finding of M. tuberculosis
strain characteristics was a geographical gradient
roughly from the southeast to the northwest. In this
direction, both drug resistance, notably streptomycin
resistance, and the contribution of the Beijing strain
family to morbidity decreased. Conversely, the contri-
bution of the EAI spoligotype family to the province
group-specific strains increased. Strain family and
region were independently associated with drug re-
sistance in the multivariable analysis. In the Mekong
river delta in Viet Nam, overall a lower transmissibility
Table 3. Spoligotype groups of Mycobacterium tuberculosis strains, by time, geographical provenance of patients,
and patient characteristics, Cambodia, Kantha Bopha hospitals, 1 January 2004 to 15 July 2008
Characteristic
EAI group Undefined Beijing Other defined
TotalNo. Row % No. Row % No. Row % No. Row %
Total 95 59·0 32 19·9 20 12·4 14 8·7 161
Any resistance
Fully susceptible 89 64·0 27 19·4 12 8·6 11 7·9 139
Any resistance 6 27·3 5 22·7 8 36·4 3 13·6 22
Enrolment phase
1 Jan. 2004 to 30 June 2005 27 65·9 4 9·8 5 12·2 5 12·2 41
1 July 2005 to 31 Mar. 2006 27 58·7 7 15·2 7 15·2 5 10·9 46
1 Apr. 2006 to 15 July 2008 41 55·4 21 28·4 8 10·8 4 5·4 74
Province group
Siem Reap group 61 70·1 13 14·9 7 8·0 6 6·9 87
Kampong Thom 16 45·7 12 34·3 4 11·4 3 8·6 35
Phnom Penh group 18 46·2 7 17·9 9 23·1 5 12·8 39
Age quartile (years)
0 to <6·6 20 50·0 10 25·0 6 15·0 4 10·0 40
6·6 to <10·9 23 59·0 9 23·1 4 10·3 3 7·7 39
10·9 to <13·1 23 57·5 7 17·5 5 12·5 5 12·5 40
513·1 29 69·0 6 14·3 5 11·9 2 4·8 42
Patient’s sex
Female 44 57·1 12 15·6 13 16·9 8 10·4 77
Male 50 64·1 18 23·1 6 7·7 4 5·1 78
Missing 1 16·7 2 33·3 1 16·7 2 33·3 6
Disease site
Intrathoracic only 41 61·2 13 19·4 8 11·9 5 7·5 67
Extrathoracic only 17 51·5 8 24·2 6 18·2 2 6·1 33
Intra- and extrathoracic 37 60·7 11 18·0 6 9·8 7 11·5 61
HIV test result
Negative 42 61·8 16 23·5 7 10·3 3 4·4 68
Positive 3 100·0 0 0·0 0 0·0 0 0·0 3
Missing 50 55·6 16 17·8 13 14·4 11 12·2 90
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Table 4. Drug susceptibility test results for isoniazid, rifampicin, and streptomycin only, by time, geographical provenance of patients, and patient characteristics,
Cambodia, Kantha Bopha hospitals, 1 January 2004 to 15 July 2008
Characteristic
Any resistance
Any SM
resistance
Any INH
resistance
Any RMP
resistance Any MDR
Fully
susceptible
TotalNo. Row % No. Row % No. Row % No. Row % No. Row % No. Row %
Total 22 13·7 14 8·7 11 6·8 4 2·5 3 1·9 139 86·3 161
Shared international type
EAI group 6 6·3 4 4·2 3 3·2 1 1·1 1 1·1 89 93·7 95
Undefined 5 15·6 1 3·1 3 9·4 2 6·3 1 3·1 27 84·4 32
Beijing group 8 40·0 7 35·0 4 20·0 0 0·0 0 0·0 12 60·0 20
Other defined 3 21·4 2 14·3 1 7·1 1 7·1 1 7·1 11 78·6 14
Enrolment phase
1 Jan. 2004 to 30 June 2005 9 22·0 6 14·6 5 12·2 2 4·9 2 4·9 32 78·0 41
1 July 2005 to 31 Mar. 2006 6 13·0 5 10·9 3 6·5 0 0·0 0 0·0 40 87·0 46
1 Apr. 2006 to 15 July 2008 7 9·5 3 4·1 3 4·1 2 2·7 1 1·4 67 90·5 74
Province group
Siem Reap group 4 4·6 1 1·1 3 3·4 1 1·1 1 1·1 83 95·4 87
Kampong Thom 6 17·1 4 11·4 3 8·6 0 0·0 0 0·0 29 82·9 35
Phnom Penh group 12 30·8 9 23·1 5 12·8 3 7·7 2 5·1 27 69·2 39
Age group (years)
0 to <6·6 8 20·0 5 12·5 4 10·0 1 2·5 1 2·5 32 80·0 40
6·6 to <10·9 2 5·1 1 2·6 0 0·0 1 2·6 0 0·0 37 94·9 39
10·9 to <13·1 6 15·0 4 10·0 3 7·5 2 5·0 2 5·0 34 85·0 40
513·1 6 14·3 4 9·5 4 9·5 0 0·0 0 0·0 36 85·7 42
Sex
Female 13 16·9 9 11·7 7 9·1 2 2·6 2 2·6 64 83·1 77
Male 7 9·0 4 5·1 4 5·1 1 1·3 1 1·3 71 91·0 78
Missing 2 33·3 1 16·7 0 0·0 1 16·7 0 0·0 4 66·7 6
Disease site
Intrathoracic only 6 9·0 6 9·0 0 0·0 0 0·0 0 0·0 61 91·0 67
Extrathoracic only 7 21·2 4 12·1 5 15·2 1 3·0 0 0·0 26 78·8 33
Intra- and extrathoracic 9 14·8 4 6·6 6 9·8 3 4·9 3 4·9 52 85·2 61
HIV test result
Negative 4 5·9 2 2·9 2 2·9 0 0·0 0 0·0 64 94·1 68
Positive 1 33·3 0 0·0 1 33·3 1 33·3 1 33·3 2 66·7 3
Missing 17 18·9 12 13·3 8 8·9 3 3·3 2 2·2 73 81·1 90
SM, Streptomycin; INH, isoniazid; RMP, rifampicin; MDR, multidrug resistance; EAI, East African-Indian.
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Table 5. Univariable and multivariable analysis of relative prevalence of any anti-tuberculosis drug resistance by
strain and patient characteristics. Cambodia, Kantha Bopha hospitals, 1 January 2004 to 15 July 2008
Characteristic
Any resistance
Total
Univariable association Multivariable association
Relative prevalence Relative prevalence
No. Row % Point 95% CI P value Point 95% CI P value
Total 22 13·7 161
Shared international type
EAI group 6 6·3 95 1 0·001 1 0·049
Undefined 5 15·6 32 2·5 (0·81–7·6) 2·0 (0·64–6·0)
Beijing 8 40·0 20 6·3 (2·5–16·3) 4·2 (1·5–11·7)
Other defined 3 21·4 14 3·4 (0·95–12·1) 2·5 (0·75–8·3)
Enrolment phase
1 Jan. 2004 to 30 June 2005 9 22·0 41 1 0·173
1 July 2005 to 31 Mar. 2006 6 13·0 46 0·59 (0·23–1·5)
1 Apr. 2006 to 15 July 2008 7 9·5 74 0·43 (0·17–1·1)
Province group
Siem Reap group 4 4·6 87 1 <0·001 1 0·025
Kampong Thom 6 17·1 35 3·7 (1·12–12·5) 3·1 (0·92–10·3)
Phnom Penh group 12 30·8 39 6·7 (2·3–19·5) 4·8 (1·5–14·9)
Age group (years)
0 to <6·6 8 20·0 40 1 0·279
6·6 to <10·9 2 5·1 39 0·26 (0·06–1·1)
10·9 to <13·1 6 15·0 40 0·75 (0·28–2·0)
513·1 6 14·3 42 0·71 (0·27–1·9)
Sex
Female 13 16·9 77 1 0·129
Male 7 9·0 78 0·53 (0·22–1·3)
Missing 2 33·3 6 2·0 (0·57–6·8)
Disease site
Respiratory only 6 9·0 67 1 0·161
Non-respiratory only 7 21·2 33 2·4 (0·86–6·5)
Respiratory and
non-respiratory
9 14·8 61 1·6 (0·62–4·4)
CI, Confidence interval; EAI, East African-Indian.
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Fig. 2. Prevalence of drug resistance, against any drug, streptomycin, and isoniazid, by province group of patient’s
provenance. Symbols (circles, squares, diamonds) are point estimates; vertical lines denote 95% confidence intervals.
Numbers in parentheses are number of child strains. Cambodia, Kantha Bopha hospitals, 1 January 2004 to 15 July 2008.
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was shown for the Beijing genotype strains, showing
relatively more fitness if streptomycin-resistant [18].
Among adults, a genotype analysis of strains from
Phnom Penh has shown that among non-multidrug-
resistant strains, Beijing genotypes accounted for
21% of the total [7] comparable to our 19% from
roughly the same area.
Two children with different genotypes were iden-
tified among several isolates obtained from each
child. In one child, the spoligotypes and correspond-
ing 15-MIRU-VNTR types were substantially differ-
ent, indicating a mixed infection. In the second
child, the differing spoligotype can be explained by
gene deletion [19, 20]. Since the introduction of geno-
typing methods, mixed infections among adults have
become recognized more frequently than previously
thought [21, 22] and have been estimated to occur at
least in 3% of tuberculous adults in rural southern
Viet Nam (neighbouring southern Cambodia) [23].
Mixed infections with M. tuberculosis in children
have not previously been reported.
Epidemiological studies in children have the distinct
advantage of reflecting characteristics of strains circu-
lating in the community in the recent past. Strains iso-
lated from adults point imprecisely to the acquisition
time due to the ill-defined incubation period of TB [1].
On a comparative time axis, drug resistance points
to a development in the recent past, while genotypes
mirror a longer evolutionary past [24]. Nevertheless,
there might be an intersection between drug resistance
and genotype, the former may differentially affect the
fitness of different genotypes, therefore the penetrating
power of certain newly emerging strains may be su-
perior [25–27].
Our analysis suggests that the observed geographi-
cal gradient was coincident rather than one confound-
ing the other. On the shorter time axis, chemotherapy,
as prerequisite for emergence of resistance, is likely to
have been present in large urban settings prior to
reaching rural settings at a time before there was a
national TB programme. In Cambodia, the emergence
of isoniazid resistance may have been facilitated by
statements of the 1964 World Health Organization
Expert Committee that was permissive to isoniazid
monotherapy during the treatment continuation
phase [28]. The problem of emerging drug resistance
was subsequently compounded by recommendations
to utilize isoniazid plus streptomycin (supplemented
by pyrazinamide during the intensive phase), a widely
used regimen in Cambodia well into the 1990s [29]. It
is thus not surprising that a substantial amount of
streptomycin resistance in adults remains as seen
in the national surveys [5, 6]. The more rational
6-month, rifampicin-throughout regimen used now-
adays in the national programme has not yet been
able to curtail transmission of streptomycin-resistant
strains to the youngest generation. We note the associ-
ation between streptomycin but not isoniazid resist-
ance with the Beijing strain type, as being reported
from the Mekong river delta in Viet Nam [30],
where the antecedents of current chemotherapy regi-
mens are similar to Cambodia [31].
The global pattern of the spoligotype families plays
out on a much grander time scale than drug resistance
[24]. It is conceivable, that changes in the genotypic
strain composition can be observed to occur relatively
rapidly in small geographical areas [32]. In a wider
regional context, the Beijing strain family is highly
prevalent in the Mekong river delta in Viet Nam
and increases with younger age, suggesting its rela-
tively rapid spread [33]. A similar observation has
been reported from Thailand (the frequency of
Beijing strains decreased with increasing distance
from the capital [34]). In China, marked geographical
variations of genotypes have been reported, the
Beijing family being the most prevalent [35]. There
is evidence from our paediatric population that the
Beijing strain family has reached the capital and its
surroundings, although to a much lesser extent than
in the neighbouring countries. It is still far from dis-
placing the EAI spoligotype that dominates in the
country and the northwest in particular.
A major weakness of our study is that it was not
embedded in a similarly representative population-
based sampling scheme as the two national drug re-
sistance surveys. Sampling in Siem Reap was rather
systematic, while in the Phnom Penh hospitals it was
less so. Thus, our overall estimate underestimates the
true prevalence of resistance in the whole of the coun-
try because the higher prevalence setting of the Phnom
Penh area is relatively underrepresented in our sample.
Drug susceptibility patterns of M. tuberculosis iso-
lated from infants and children reflect the character-
istics of most recently transmitted strains currently
circulating within the population [1]. The deterio-
ration of the situation in South Africa has been docu-
mented in such a way in an exemplary fashion [3]. It is
exceedingly difficult to obtain clinical isolates from
children to assess the resistance situation, in fact,
they are often specifically excluded. In a large national
drug resistance survey in 2000–2001 in Cambodia,
including 734 strains from patients with sputum
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smear-positive TB, fewer than 10% of participants
were aged <25 years, and children were virtually en-
tirely absent [5]. In the national prevalence survey
2002, 245 strains were tested for drug susceptibility
[6] to isoniazid, rifampicin, ethambutol and strepto-
mycin. Children aged <10 years were exempted from
radiographic and bacteriological examinations be-
cause of the technical difficulties with these procedures
in children.
The prevalence of any resistance in the 2000–2001
national drug resistance survey and the 2002 national
TB survey was 7·8% and 11·3%, respectively. This
compares to 13·7% (or 14·3% if we include ethambu-
tol but not pyrazinamide to make it comparable) in
the current survey. Although the differences were
small, we note the higher point estimate among our
children. In contrast to the two national surveys, our
sample size was not geographically balanced. While
there is thus a sampling bias between geographical
areas, there is much less of a bias in the ascertainment
of genotypes and resistance prevalence within a geo-
graphical region. This latter demonstrates that resist-
ance prevalence around the capital is worrisomely
higher than in the more peripheral areas that were
relatively overrepresented in our study. The crude
prevalence of drug resistance underestimates the prob-
lem among children in the country. A higher preva-
lence in children than adults for a drug like isoniazid
that has always been used for all patients points to
an increase in the magnitude of the problem over
time [1, 36]
Cambodia is one of the 22 high-burden countries
which comprise 80% of the estimated global TB inci-
dence. Over the past decade, TB in Cambodia has
declined [37]. Childhood TB might also decrease, par-
ticularly if case finding and treatment among adult
sources of transmission can further be strengthened.
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